Obeticholic Acid

Product introduction:

Obeticolic acid, also known as 6-ethyl chenodeoxycholic acid, is a new derivative of chenodeoxycholic acid (CDCA) in human primary bile acids. It is a natural ligand of farneside derivative X receptor (FXR). Obecholic acid is a farnesol X receptor agonist, which indirectly inhibits the gene expression of cytochrome 7a1 (CYP7A1) by activating farnesol X receptor. Because CYP7A1 is the rate limiting enzyme of cholic acid biosynthesis, OBE cholic acid can inhibit cholic acid synthesis and be used to treat primary biliary cirrhosis and nonalcoholic fatty liver disease.

CAS：459789-99-2

Molecular formula: C₂₆H₄₄O₄

Molecular weight: 420.63

Structural type:

Product purpose:

Studies have shown that insulin resistance plays an important role in the pathogenesis of NAFLD / NASH. Insulin sensitizers such as thiazolidinediones have been proved to be effective in improving liver inflammation and fat content, but they can not block the progression of fibrosis caused by Nash. Farneside derivative X receptor also improves insulin resistance and plays an important role in the metabolism of bile acids, lipids and sugars.